Radezolid
In-game article clicks load inline without leaving the challenge.
Radezolid (INN, codenamed RX-1741) is a novel oxazolidinone antibiotic being developed by Melinta Therapeutics, Inc. for the treatment of bacterial acne.
Further reading
- Zhou J, Bhattacharjee A, Chen S, et al. (December 2008). "Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics". Bioorg. Med. Chem. Lett. 18 (23): 6175–8. doi:. PMID .
- Skripkin E, McConnell TS, DeVito J, et al. (October 2008). . Antimicrob. Agents Chemother. 52 (10): 3550–7. doi:. PMC . PMID .
- Lawrence L, Danese P, DeVito J, Franceschi F, Sutcliffe J (May 2008). . Antimicrob. Agents Chemother. 52 (5): 1653–62. doi:. PMC . PMID .
- Hanselmann R, Job G, Johnson G, Lou R, Martynow JG, Reeve MM (2009). "Synthesis of an antibacterial compound containing a 1,4-substituted 1H-1,2,3-triazole- a scaleable [sic] alternative to the "click" reaction"". Organic Process Research & Development. 14: 152–158. doi:.
- Franceschi F, Duffy EM (March 2006). "Structure-based drug design meets the ribosome". Biochem. Pharmacol. 71 (7): 1016–25. doi:. PMID .
- Ohlsen K (November 2009). "Novel antibiotics for the treatment of Staphylococcus aureus". Expert Rev. Clin. Pharmacol. 2 (6): 661–72. doi:. PMID . S2CID .